보고서 요약(국문)

시장 개요
전 세계 진통제 시장 규모는 2022년 YY백만 달러였으며, 2030년에는 YY백만 달러에 이를 것으로 예상됩니다. 예측 기간(2023-2030년) 동안 연평균 성장률(CAGR)은 YY%입니다.
통증은 조직 손상이나 질병으로 인해 발생하는 고통스러운 감각입니다. 위궤양, 경화증, 골관절염, 만성 관절염, 당뇨병성 신경병증, 암 등 다양한 질환이 통증을 유발할 수 있습니다. 통증 지속 기간에 따라 만성 통증은 장기간 지속되는 만성 통증과 수개월, 수주 또는 수일 동안 지속되는 단기 급성 통증으로 나뉩니다. 만성 통증은 수년간 지속됩니다.
시장 동향
환자의 삶의 질 향상을 위한 진통제 수요 증가가 예측 기간 동안 전 세계 진통제 시장 성장을 견인하고 있습니다.
진통제에 대한 수요 증가가 전 세계 시장 성장을 촉진하고 있습니다.

진통제는 수술 후 통증, 심각한 신체 부상, 암으로 인한 통증과 같은 극심한 통증을 완화하는 데 사용됩니다. 또한 다른 유형의 만성 통증에도 사용됩니다. 수술 후 통증, 신체 외상, 관절염 및 암과 같은 만성 비전염성 질환의 증가로 진통제에 대한 수요가 증가하고 있습니다. 예를 들어, 세계보건기구(WHO)에 따르면 매년 수백만 명이 비치명적인 부상을 입어 입원하거나 일반의 또는 응급실 및 급성 치료 시설을 방문하며, 종종 일시적 또는 영구적인 장애를 겪습니다. 또한, 국제암연구기관(IARC)은 2020년에 전 세계적으로 약 1,929만 2,789건의 다양한 유형의 암 신규 환자가 발생했다고 추산했습니다. 마찬가지로, 세계 류마티스 관절염 네트워크(Global Rheumatoid Arthritis Network)에 따르면 2021년에 약 3억 5천만 명이 관절염을 앓았습니다. 또한, 미국 국립보건원(NIH)은 수술을 받은 환자의 75% 이상이 중등도에서 고강도에 이르는 급성 수술 후 통증을 경험한다고 밝혔습니다.
또한, 전 세계적으로 수술 건수가 증가함에 따라 전 세계 진통제 시장도 확대되고 있습니다. 예를 들어, 유럽 핵심 건강 지표(ECHI)에 따르면 EU 병원에서 가장 많이 시행된 수술은 백내장 수술과 제왕절개였습니다. 2020년 EU 회원국 전체에서 백내장 수술은 366만 건이 시행되었고, 제왕절개는 같은 해 EU에서 최소 112만 건이 시행되었습니다.
다른 진통 치료법의 도입 및 보급은 전 세계 시장 성장에 주요 장애물로 작용합니다.
하지만 경피 전기 신경 자극(TENS) 요법과 같이 저전압 전류를 이용하여 통증을 치료하는 다른 진통 치료법의 도입 및 보급이 가능해지고 있습니다. 또한, 2021년 1월 보스턴 사이언티픽(Boston Scientific Corporation)은 개인 맞춤형 통증 완화를 위한 다양한 치료 옵션을 제공하는 척수 자극기(SCS) 시스템 포트폴리오인 웨이브라이터 알파(WaveWriter Alpha)를 출시했습니다.

COVID-19 영향 분석
COVID-19 팬데믹은 전 세계 진통제 시장에 큰 영향을 미쳤습니다. 특히 COVID-19 감염이 근육통, 방사통, 광범위한 과민증과 관련이 있다는 증거가 늘어나면서, 코로나19 팬데믹 기간 동안 만성 통증 관리는 더욱 어려워졌습니다. 경증에서 중등도 통증 완화를 위한 다중 진통 요법의 일환으로 비마약성 진통제(NSAID)는 단독 또는 비스테로이드성 항염증제(NSAID)와 병용하여 사용되지만, 발열, 두통, 급성 또는 만성 통증과 같은 COVID-19 증상 완화에도 안전하게 사용될 수 있어 진통제 수요가 증가하고 시장 성장에 긍정적인 영향을 미쳤습니다.
세그먼트 분석
만성 통증 유형은 예측 기간(2022-2029년) 동안 전 세계 진통제 시장에서 큰 비중을 차지할 것으로 예상됩니다.

만성 통증 유형은 예측 기간 동안 시장 점유율의 대부분을 차지할 것으로 전망됩니다. 존스 홉킨스 병원에 따르면, 만성 통증은 정상적인 치유 기간을 넘어 지속되거나 관절염, 암성 통증, 편두통, 군발성 두통 등과 같은 만성 질환과 함께 나타나는 장기적인 통증을 말합니다. 만성 통증은 나타났다 사라지기를 반복하거나 지속적으로 나타날 수 있습니다. 미국은 연간 3조 5천억 달러를 의료비로 지출하며, 그중 90%가 만성 통증을 포함한 만성 질환 치료에 사용됩니다. 또한, 의학 저널 란셋(The Lancet)의 한 기사에 따르면, 만성 통증은 전 세계적으로 30% 이상의 사람들에게 영향을 미치며 개인적, 경제적으로 막대한 부담을 안겨줍니다. 미국 국립보건원(NIH)에 따르면, 만성 통증은 노년층에서 특히 흔하며, 상당한 고통, 장애, 사회적 고립, 그리고 의료 시스템에 대한 높은 비용 부담과 관련이 있습니다. 따라서, 노년 인구의 증가는 만성 통증 시장의 성장에 기여하고 있습니다. 예를 들어, WHO에 따르면 2020년 노인 인구는 10억 명이었으며 2030년에는 14억 명에 이를 것으로 예측됩니다. 따라서 위에서 언급한 데이터는 만성 통증이 전 세계 진통제 시장을 주도할 것임을 시사합니다.
지역 분석
북미는 예측 기간(2022-2029년) 동안 전 세계 진통제 시장을 주도할 것으로 예상됩니다.
만성 질환 발생 건수가 많고 주요 시장 참여 기업들이 존재하기 때문에 북미 진통제 시장은 예측 기간(2022-2029년) 동안 높은 연평균 성장률(CAGR)을 기록할 것으로 전망됩니다. 예를 들어, 미국 암 협회의 추산에 따르면 2022년 미국에서는 약 190만 건의 새로운 암 사례가 발생하고 약 609,360명이 암으로 사망할 것으로 예상됩니다. 마찬가지로, 미국 질병통제예방센터(CDC)는 2040년까지 약 7,800만 명의 미국 성인이 의사의 진단을 받은 관절염을 앓게 될 것으로 예상했으며, 이는 진통제 수요 증가로 이어질 것입니다. 또한, 존슨앤존슨, 화이자, 퍼듀파마, 엔도인터내셔널, 마일란, 임팩스 래버러토리스, 인디비어 등 시장 점유율이 높은 주요 업체들이 대부분 미국에 기반을 두고 있어 북미 지역이 세계 진통제 시장을 주도하고 있습니다. 따라서 위의 자료를 바탕으로 예측 기간(2022-2029년) 동안 북미 지역이 세계 진통제 시장의 대부분을 차지할 것으로 예상됩니다.

경쟁 환경
진통제 시장은 진통제 수요 증가와 국내외 주요 업체들의 경쟁으로 인해 비교적 경쟁이 치열한 양상을 보입니다. 주요 업체로는 Pfizer Inc., Johnson & Johnson Services Inc., Bayer AG, Sanofi S.A., GlaxoSmithKline plc., Bristo-Meyers Squibb and Company, Teva Pharmaceutical Industries Ltd., Mylan N.V., Merck & Co., 그리고 Cardinal Health Inc. 등이 있습니다. 이들 업체는 인수, 신제품 출시, 그리고 협력을 통해 시장을 장악하고 있습니다. 예를 들어, Venus Remedies Limited는 2021년 7월 통증 관리를 위한 다양한 제품을 제공하는 소비자 건강 관리 사업부를 출범시켰습니다.
Teva Pharmaceutical Industries Ltd.
개요
Teva Pharmaceuticals는 1901년 예루살렘에서 설립되었습니다. 현재 세계 15대 제약 회사 중 하나입니다. Teva는 3,600개 이상의 의약품을 보유하고 있으며, 전 세계적으로 37,000명의 직원과 53개의 생산 시설을 운영하고 있습니다.
제품 포트폴리오:
Teva Pharmaceuticals의 진통제 제품 포트폴리오에는 다음과 같은 약물이 포함됩니다. 히드로모르폰은 오피오이드 진통제 계열에 속합니다. 이 약은 수술 후 통증과 같은 중등도에서 중증의 통증을 치료하는 데 사용됩니다.
글로벌 진통제 시장 보고서는 약 40개 이상의 시장 데이터 표, 45개 이상의 그림, 그리고 약 200페이지 분량의 자료를 제공합니다.

보고서 요약(영어 원문)

Market Overview
The global pain relief medication size was valued at US$ YY million in 2022 and is estimated to reach US$ YY million by 2030, growing at a CAGR of YY% during the forecast period (2023-2030).
Pain is a troubling sensation developed because of tissue injury or disease. Various conditions can induce distress, like abdominal ulcers, sclerosis, osteoarthritis, chronic arthritis, diabetic neuropathy, and cancer. Based on the duration of pain, sensation pain is of two types chronic, lasting for the long term, and acute pain for the short term, which can last for months, weeks, or days. In contrast, chronic pain lasts for years.
Market Dynamics
The rising need for pain-relieving medication to increase the patient quality of life is boosting the global pain-relief medication market growth during the forecast period.
The growing demand for pain-relieving medication is fueling the market growth globally.
Pain Relief Medications alleviate extreme pain in conditions such as post-surgery pain, a serious physical injury, or pain from cancer. They are also used for other types of long-standing pain. The growing number of postoperative pains, physical traumas and chronic non-communicable diseases such as arthritis and cancer are creating the demand for Pain Relief Medication. For instance, according to the WHO, more than millions suffer non-fatal injuries each year, which lead to hospitalizations or treatment by general practitioners or emergency department and acute care visits and often result in temporary or permanent disability. Also, the International Agency for Research on Cancer WHO assessed there were about 19292789 new cases of different types of cancer globally in 2020. Similarly, according to the Global Rheumatoid Arthritis Network, approximately 350 million people lived with arthritis in 2021. Additionally, the NIH states that over 75% of the patients who have undergone surgery experience acute postoperative pain, which might be medium to high in severity.
Furthermore, the increasing number of surgeries performed globally also expands the global pain relief medication market. For instance, according to the European core health indicators (ECHI), the two most common surgical operations and procedures performed in EU hospitals were cataract surgery and cesarean sections. Cataract surgery was conducted 3.66 million times in 2020 across the EU Member States. At the same time, the cesarean section procedure was performed at least 1.12 million times in the EU in 2020.
The availability and introduction of other pain-relieving treatments is a major hurdle in the market's global growth.
However, the availability and introduction of other pain relieving treatments, such as Transcutaneous Electrical Nerve Stimulation (TENS) therapy, involves using low-voltage electric currents to treat pain. Furthermore, in January 2021, Boston Scientific Corporation introduced the WaveWriter Alpha, a portfolio of Spinal Cord Stimulator (SCS) systems that incorporate treatment choices for personalized pain relief.
COVID-19 Impact Analysis
The COVID-19 pandemic has greatly impacted the global pain relief medication market. Chronic pain management during the coronavirus disease 2019 (COVID-19) pandemic was difficult, particularly with rising proof that COVID-19 infection is associated with myalgias, referred pain, and widespread hyperalgesia. Non-Opioid Analgesic medication used alone or in combination with non-steroidal anti-inflammatory drugs (NSAIDs) in addressing mild-to-moderate pain as part of multimodal analgesia, also be utilized safely to relieve symptoms of COVID-19, like fever, headache, and acute or chronic pain, which led to increased demand for pain relief medication and positively impacted the market growth.
Segment Analysis
The chronic pain type is predicted to hold a large share of the global pain relief medication market during the forecast period (2022-2029).
The chronic pain type is expected to hold most of the market share during the forecasted period. According to the Johns Hopkins Hospital, Chronic pain is long-standing pain that lasts beyond the normal healing period or surfaces along with a chronic health condition, like arthritis, Cancer pain, migraines, cluster headaches and others. Chronic pain may be "appearing" and "disappearing" or continuous. The U.S. spends $3.5 trillion annually on health care, with 90% of that going to chronic conditions, including chronic pain. Moreover, according to an article by The Lancet, Chronic pain exerts an immense individual and financial hindrance, impacting over 30% of individuals worldwide. Also, according to the NIH, Chronic pain is favorably dominant among geriatric adults, associated with substantial suffering, disability, social solitariness, and higher expenditures and burden to health care systems. Thus, the growing geriatric population is contributing to the growth of the chronic pain segment. For example, according to WHO, the geriatric population accounted for 1 billion in 2020 and is predicted to reach 1.4 billion by 2030. Thus the data mentioned above indicate that the chronic pain type will dominate the global pain relief medication market
Geographical Analysis
North America oppresses the global pain relief medication market throughout the forecast period (2022-2029).
Owing to the high number of chronic disease cases and the presence of key market players, the North American pain relief medication market is assessed to grow at a high CAGR in the forecast period (2022-2029). Such as, according to the American cancer society estimations, in 2022, about 1.9 million new cancer cases will be analyzed, and around 609,360 cancer-caused deaths in the United States. Likewise, CDC anticipated that approximately 78 million U.S. adults will live with doctor-diagnosed arthritis in 2040, increasing the demand for the Pain Relief Medication analgesic. Similarly, the major key players holding a larger share of the market are U.S. based, such as Johnson & Johnson, Pfizer Inc., Purdue Pharma, Endo International, Mylan, Impax Laboratories and Indivior, contributing to the dominance of North America over the global Pain Relief Medication market. Therefore from the data mentioned above, it is anticipated that North America will hold most of the global pain relief medication market throughout the forecasted period (2022-2029).
Competitive Landscape
The pain relief medication market is moderately competitive since there is a growing demand for pain relief medication and local and global key players. Some key players are Pfizer Inc., Johnson & Johnson Services Inc., Bayer AG, Sanofi S.A., GlaxoSmithKline plc., Bristo-Meyers Squibb and Company, Teva Pharmaceutical Industries Ltd., Mylan N.V., Merck & Co., and Cardinal Health Inc. These key players hold the market through acquisition, product launches, and collaborations. For instance, in July 2021, Venus Remedies Limited launched a consumer healthcare division that will offer various products for pain management.
Teva Pharmaceutical Industries Ltd.
Overview
Teva Pharmaceuticals was founded in 1901 in Jerusalem. It is today among the top 15 pharmaceutical companies worldwide. Teva has over 3600 medicines in its product portfolio, with 37,000 employees working globally and 53 production sites globally.
Product Portfolio:
Teva Pharmaceutical’s product portfolio of pain relief medication has: Hydromorphone comes under the family of drugs known as opioid painkillers. It is employed to treat moderate-to-severe pain, such as pain after surgery.
The global pain relief medication market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Market Definition and Overview
3. Executive Summary
4. Market Dynamics
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.1.1. The Growing Demand for Pain Relief Medication
4.1.1.2. Growing Geriatric Population
4.1.2. Restraints
4.1.2.1. Availability of Other Options
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Forces Analysis
5.2. Supply Chain Analysis
5.3. Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturer’s Strategic Initiatives
6.6. Conclusion
7. By Route of Administration
7.1. Introduction
7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
7.1.2. Market Attractiveness Index, By Route of Administration
7.2. Oral
7.2.1. Introduction
7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
7.3. Injectable
7.4. Topical
8. By Type
8.1. Introduction
8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
8.1.2. Market Attractiveness Index, By Type
8.2. Acute
8.2.1. Introduction
8.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
8.3. Chronic
9. By Distribution Channel
9.1. Introduction
9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
9.1.2. Market Attractiveness Index, By Distribution Channel
9.2. Hospital Pharmacy
9.2.1. Introduction
9.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
9.3. Retail Pharmacy
9.4. Online Pharmacy
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. U.K.
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
11. Competitive Landscape
11.1. Key Developments and Strategies
11.2. Company Share Analysis
11.3. Product Benchmarking
12. Company Profiles
12.1. Teva Pharmaceutical Industries Ltd.
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Key Highlights
12.1.4. Financial Overview
12.2. Pfizer Inc.
12.3. Johnson & Johnson Services Inc.
12.4. Bayer AG
12.5. Sanofi S.A.
12.6. GlaxoSmithKline plc.
12.7. Bristo-Meyers Squibb and Company
12.8. Mylan N.V.
12.9. Merck & Co.
12.10. Cardinal Health Inc.
LIST NOT EXHAUSTIVE
13. DataM
13.1. Appendix
13.2. About Us and Services
13.3. Contact Us

언급된 주요 기업들

Teva Pharmaceutical Industries Ltd., Pfizer Inc., Johnson & Johnson Services Inc., Bayer AG, Sanofi S.A., GlaxoSmithKline plc., Bristo-Meyers Squibb and Company, Mylan N.V., Merck & Co., Cardinal Health Inc.

표 목록 (Tables)

List of Tables

Table 1 Global Pain Relief Medication Market Value, By Drug Class, 2022, 2026 & 2030 ($ Million)

Table 2 Global Pain Relief Medication Market Value, By Type, 2022, 2026 & 2030 ($ Million)

Table 3 Global Pain Relief Medication Market Value, By Route of Administration, 2022, 2026 & 2030 ($ Million)

Table 4 Global Pain Relief Medication Market Value, By Distribution Channel, 2022, 2026 & 2030 ($ Million)

Table 5 Global Pain Relief Medication Market Value, By Region, 2022, 2026 & 2030 ($ Million)

Table 6 Global Pain Relief Medication Market Value, By Drug Class, 2022, 2026 & 2030 ($ Million)

Table 7 Global Pain Relief Medication Market Value, By Drug Class, 2021-2030 ($ Million)

Table 8 Global Pain Relief Medication Market Value, By Type, 2022, 2026 & 2030 ($ Million)

Table 9 Global Pain Relief Medication Market Value, By Type, 2021-2030 ($ Million)

Table 10 Global Pain Relief Medication Market Value, By Route of Administration, 2022, 2026 & 2030 ($ Million)

Table 11 Global Pain Relief Medication Market Value, By Route of Administration, 2021-2030 ($ Million)

Table 12 Global Pain Relief Medication Market Value, By Distribution Channel, 2022, 2026 & 2030 ($ Million)

Table 13 Global Pain Relief Medication Market Value, By Distribution Channel, 2021-2030 ($ Million)

Table 14 Global Pain Relief Medication Market Value, By Region, 2022, 2026 & 2030 ($ Million)

Table 15 Global Pain Relief Medication Market Value, By Region, 2021-2030 ($ Million)

Table 16 North America Pain Relief Medication Market Value, By Drug Class, 2021-2030 ($ Million)

Table 17 North America Pain Relief Medication Market Value, By Type, 2021-2030 ($ Million)

Table 18 North America Pain Relief Medication Market Value, By Route of Administration, 2021-2030 ($ Million)

Table 19 North America Pain Relief Medication Market Value, By Distribution Channel, 2021-2030 ($ Million)

Table 20 North America Pain Relief Medication Market Value, By Country, 2021-2030 ($ Million)

Table 21 South America Pain Relief Medication Market Value, By Drug Class, 2021-2030 ($ Million)

Table 22 South America Pain Relief Medication Market Value, By Type, 2021-2030 ($ Million)

Table 23 South America Pain Relief Medication Market Value, By Route of Administration, 2021-2030 ($ Million)

Table 24 South America Pain Relief Medication Market Value, By Distribution Channel, 2021-2030 ($ Million)

Table 25 South America Pain Relief Medication Market Value, By Country, 2021-2030 ($ Million)

Table 26 Europe Pain Relief Medication Market Value, By Drug Class, 2021-2030 ($ Million)

Table 27 Europe Pain Relief Medication Market Value, By Type, 2021-2030 ($ Million)

Table 28 Europe Pain Relief Medication Market Value, By Route of Administration, 2021-2030 ($ Million)

Table 29 Europe Pain Relief Medication Market Value, By Distribution Channel, 2021-2030 ($ Million)

Table 30 Europe Pain Relief Medication Market Value, By Country, 2021-2030 ($ Million)

Table 31 Asia-Pacific Pain Relief Medication Market Value, By Drug Class, 2021-2030 ($ Million)

Table 32 Asia-Pacific Pain Relief Medication Market Value, By Type, 2021-2030 ($ Million)

Table 33 Asia-Pacific Pain Relief Medication Market Value, By Route of Administration, 2021-2030 ($ Million)

Table 34 Asia-Pacific Pain Relief Medication Market Value, By Distribution Channel, 2021-2030 ($ Million)

Table 35 Asia-Pacific Pain Relief Medication Market Value, By Country, 2021-2030 ($ Million)

Table 36 Middle East & Africa Pain Relief Medication Market Value, By Drug Class, 2021-2030 ($ Million)

Table 37 Middle East & Africa Pain Relief Medication Market Value, By Type, 2021-2030 ($ Million)

Table 38 Middle East & Africa Pain Relief Medication Market Value, By Route of Administration, 2021-2030 ($ Million)

Table 39 Middle East & Africa Pain Relief Medication Market Value, By Distribution Channel, 2021-2030 ($ Million)

Table 40 Pfizer Inc.: Overview

Table 41 Pfizer Inc.: Product Portfolio

Table 42 Pfizer Inc.: Key Developments

Table 43 Johnson & Johnson Services Inc.: Overview

Table 44 Johnson & Johnson Services Inc.: Product Portfolio

Table 45 Johnson & Johnson Services Inc.: Key Developments

Table 46 Bayer AG: Overview

Table 47 Bayer AG: Product Portfolio

Table 48 Bayer AG: Key Developments

Table 49 Sanofi S.A.: Overview

Table 50 Sanofi S.A.: Product Portfolio

Table 51 Sanofi S.A.: Key Developments

Table 52 GlaxoSmithKline plc.: Overview

Table 53 GlaxoSmithKline plc.: Product Portfolio

Table 54 GlaxoSmithKline plc.: Key Developments

Table 55 Bristo-Meyers Squibb and Company: Overview

Table 56 Bristo-Meyers Squibb and Company: Product Portfolio

Table 57 Bristo-Meyers Squibb and Company: Key Developments

Table 58 Teva Pharmaceutical Industries Ltd.: Overview

Table 59 Teva Pharmaceutical Industries Ltd.: Product Portfolio

Table 60 Teva Pharmaceutical Industries Ltd.: Key Developments

Table 61 Mylan N.V.: Overview

Table 62 Mylan N.V.: Product Portfolio

Table 63 Mylan N.V.: Key Developments

Table 64 Merck & o.: Overview

Table 65 Merck & o.: Product Portfolio

Table 66 Merck & o.: Key Developments

Table 67 Cardinal Health Inc.: Overview

Table 68 Cardinal Health Inc.: Product Portfolio

Table 69 Cardinal Health Inc.: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Pain Relief Medication Market Share, By Drug Class, 2022 & 2030 (%)

Figure 2 Global Pain Relief Medication Market Share, By Type, 2022 & 2030 (%)

Figure 3 Global Pain Relief Medication Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 4 Global Pain Relief Medication Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 5 Global Pain Relief Medication Market Share, By Region, 2022 & 2030 (%)

Figure 6 Global Pain Relief Medication Market Value, 2021-2030 ($ Million)

Figure 7 Global Pain Relief Medication Market Y-o-Y Growth, By Drug Class, 2022-2030 (%)

Figure 8 NSAIDs: Global Pain Relief Medication Market Value, 2021-2030 ($ Million)

Figure 9 Opioids: Global Pain Relief Medication Market Value, 2021-2030 ($ Million)

Figure 10 Anesthetics: Global Pain Relief Medication Market Value, 2021-2030 ($ Million)

Figure 11 Antidepressants: Global Pain Relief Medication Market Value, 2021-2030 ($ Million)

Figure 12 Others: Global Pain Relief Medication Market Value, 2021-2030 ($ Million)

Figure 13 Global Pain Relief Medication Market Y-o-Y Growth, By Type, 2022-2030 (%)

Figure 14 Chronic: Global Pain Relief Medication Market Value, 2021-2030 ($ Million)

Figure 15 Acute: Global Pain Relief Medication Market Value, 2021-2030 ($ Million)

Figure 16 Global Pain Relief Medication Market Y-o-Y Growth, By Route of Administration, 2022-2030 (%)

Figure 17 Oral: Global Pain Relief Medication Market Value, 2021-2030 ($ Million)

Figure 18 Topical: Global Pain Relief Medication Market Value, 2021-2030 ($ Million)

Figure 19 Injectable: Global Pain Relief Medication Market Value, 2021-2030 ($ Million)

Figure 20 Global Pain Relief Medication Market Y-o-Y Growth, By Distribution Channel, 2022-2030 (%)

Figure 21 Hospital Pharmacy: Global Pain Relief Medication Market Value, 2021-2030 ($ Million)

Figure 22 Retail Pharmacy: Global Pain Relief Medication Market Value, 2021-2030 ($ Million)

Figure 23 Online Pharmacy: Global Pain Relief Medication Market Value, 2021-2030 ($ Million)

Figure 24 Global Pain Relief Medication Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 25 North America Pain Relief Medication Market Value, 2021-2030 ($ Million)

Figure 26 North America Pain Relief Medication Market Share, By Drug Class, 2022 & 2030 (%)

Figure 27 North America Pain Relief Medication Market Share, By Type, 2022 & 2030 (%)

Figure 28 North America Pain Relief Medication Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 29 North America Pain Relief Medication Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 30 North America Pain Relief Medication Market Share, By Country, 2022 & 2030 (%)

Figure 31 South America Pain Relief Medication Market Value, 2021-2030 ($ Million)

Figure 32 South America Pain Relief Medication Market Share, By Drug Class, 2022 & 2030 (%)

Figure 33 South America Pain Relief Medication Market Share, By Type, 2022 & 2030 (%)

Figure 34 South America Pain Relief Medication Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 35 South America Pain Relief Medication Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 36 South America Pain Relief Medication Market Share, By Country, 2022 & 2030 (%)

Figure 37 Europe Pain Relief Medication Market Value, 2021-2030 ($ Million)

Figure 38 Europe Pain Relief Medication Market Share, By Drug Class, 2022 & 2030 (%)

Figure 39 Europe Pain Relief Medication Market Share, By Type, 2022 & 2030 (%)

Figure 40 Europe Pain Relief Medication Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 41 Europe Pain Relief Medication Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 42 Europe Pain Relief Medication Market Share, By Country, 2022 & 2030 (%)

Figure 43 Asia-Pacific Pain Relief Medication Market Value, 2021-2030 ($ Million)

Figure 44 Asia-Pacific Pain Relief Medication Market Share, By Drug Class, 2022 & 2030 (%)

Figure 45 Asia-Pacific Pain Relief Medication Market Share, By Type, 2022 & 2030 (%)

Figure 46 Asia-Pacific Pain Relief Medication Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 47 Asia-Pacific Pain Relief Medication Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 48 Asia-Pacific Pain Relief Medication Market Share, By Country, 2022 & 2030 (%)

Figure 49 Middle East & Africa Pain Relief Medication Market Value, 2021-2030 ($ Million)

Figure 50 Middle East & Africa Pain Relief Medication Market Share, By Drug Class, 2022 & 2030 (%)

Figure 51 Middle East & Africa Pain Relief Medication Market Share, By Type, 2022 & 2030 (%)

Figure 52 Middle East & Africa Pain Relief Medication Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 53 Middle East & Africa Pain Relief Medication Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 54 Pfizer Inc.: Financials

Figure 55 Johnson & Johnson Services Inc.: Financials

Figure 56 Bayer AG: Financials

Figure 57 Sanofi S.A.: Financials

Figure 58 GlaxoSmithKline plc.: Financials

Figure 59 Bristo-Meyers Squibb and Company: Financials

Figure 60 Teva Pharmaceutical Industries Ltd.: Financials

Figure 61 Mylan N.V.: Financials

Figure 62 Merck & o.: Financials

Figure 63 Cardinal Health Inc.: Financials

세계 진통제 시장 – 2023-2030

Global Pain Relief Medication Market - 2023-2030